Pluri Inc.
No SEC Form 4 filings for $PLUR in the last 30 days.
See all $PLUR insider activity →Pluri Inc. (PLUR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 26, 2026, Pluri Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”) pursuant to which the Company agreed to issue and s
Pluri Inc. (PLUR) said Chairman Alejandro Weinstein invested over $17 million in the past year, including a $1.25 million advance investment in June 2026 under an Advance Subscription Agreement. The company said he now owns more than 30% of issued shares. Pluri linked the purchases to its shift toward U.S. commercialization and longevity focus.
Pluri Inc. (PLUR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001158780 0001158780 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report
Over the past 7 days, alphai's AI scored 1 news story mentioning PLUR (Pluri Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PLUR coverage spans financial news, corporate actions and market movers.
The modest capital raise provides short‑term liquidity for corporate development but is unlikely to move the stock significantly.
The filing is a bullish insider-commitment signal and may support sentiment around Pluri’s commercialization push, but it is not a new operating milestone.
The disclosed $1.25M advance improves near-term liquidity and signals an upcoming financing pathway, but dilution risk remains tied to whether the Offering closes.
The article is a pure price-action/momentum update: a fresh 52-week low signals elevated downside risk and weak demand.
The successful expansion of Pluri (PLUR) and Remedy Cell's manufacturing collaboration signifies progress in cell-free therapeutics for fibrotic diseases. This development could positively influence PLUR's stock, especially considering its somewhat bullish sentiment.
alphai scores every news story that mentions PLUR with an AI model for sentiment and relevance, and aggregates insider trades from Pluri Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pluri Inc. (PLUR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 26, 2026, Pluri Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”) pursuant to which the Company agreed to issue and s
1 min readPluri Inc. (PLUR) said Chairman Alejandro Weinstein invested over $17 million in the past year, including a $1.25 million advance investment in June 2026 under an Advance Subscription Agreement. The company said he now owns more than 30% of issued shares. Pluri linked the purchases to its shift toward U.S. commercialization and longevity focus.
3 min readPluri Inc. (PLUR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001158780 0001158780 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report
4 min readPlurilock Security Inc. (CVE:PLUR) hit a new 52-week low in Thursday trading, falling to C$0.11 and last trading at C$0.10 versus a prior close of C$0.10. Volume was 16,024 shares. The stock’s market cap is C$7.96 million, with 50-day and 200-day moving averages of C$0.11 and C$0.16, respectively.
1 min readPluri (PLUR) and Remedy Cell have expanded their manufacturing collaboration after PluriCDMO successfully implemented Remedy Cell's proprietary process, conducted GMP training, and produced clinical-grade batches for a planned Phase 1b trial. This milestone marks significant progress for Remedy Cell's cell-free therapeutics for fibrotic conditions and reinforces PluriCDMO's role as a key manufacturing partner for complex biologics. The expanded agreement will see PluriCDMO continue to support Remedy Cell's clinical and pre-commercial programs.
2 min readHAIFA, Israel, Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Pluri Inc. ( "Pluri", the "Company", "we", "our" or "us" ) ( Nasdaq, TASE: PLUR ) , a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces the ...
4 min read
